Objective. IFN a Kinoid (IFN-K) is a therapeutic vaccine composed of IFNa2b coupled to a carrier protein.
Introduction IFN a-kinoid (IFN-K) is a therapeutic vaccine composed of inactivated IFNa2b coupled to a carrier protein. When administered to human IFNa transgenic mice, IFN-K induced a polyclonal antibody (Ab) response that neutralized all 13 human IFNa subtypes, but not IFNb or IFNg [1] . In lupusprone NZB/W mice, mouse IFN-K prevented disease manifestations (death, renal disease) triggered by exogenous IFNa [2] .
IFN-K was tested in a placebo-controlled phase I/II study including 28 SLE patients. We previously reported our observations up to day 168 after the first IFN-K injection. IFN-K induced 10Â higher anti-IFNa binding Abs in IFN gene signaturepositive (two/three of the patients) compared with IFN gene signaturenegative individuals. In these IFN-signaturepositive patients, IFN-K administration resulted in a significant decrease in the expression of IFN-induced genes, and the amplitude of the inhibition correlated with binding anti-IFNa Ab titres [3, 4] .
Here, we report on the characterization of the neutralizing anti-IFNa Ab response induced by IFN-K in the phase I/II-included patients. We also analysed extended followup data obtained in six IFN-Ktreated patients in order to obtain transcriptomic and biological insights into the longterm effects of the drug.
Patients and methods
Twenty-eight patients with SLE (aged 1850 years), according to the ACR criteria for SLE [5] , were recruited in a multicentre, randomized, double-blind placebocontrolled, phase I/II staggered dose-escalation trial of IFN-K (ClinicalTrials.gov registry number NCT01058343). Patients were randomized to receive three or four injections of placebo (n = 7) or 30 mg (n = 3), 60 mg (n = 6), 120 mg (n = 6) or 240 mg (n = 6) IFN-K. Clinical and safety data, induction of anti-IFNa Ab and gene expression profiling studies for up to day 168 after the first IFN-K injection were reported previously [3] . Institutional ethics committee approval for the present follow-up study was obtained for all participating centres. All subjects provided written informed consent.
Follow-up sera were obtained every 3 months after the last study visit in a majority of patients, up to day 336 in placebo-treated, and up to day 1558 in IFN-K treated patients. In six patients, whole blood samples were collected in PAXgene Blood RNA tubes (Qiagen, Courtaboeuf, France) every 6 months during follow-up, together with biological (binding and neutralizing anti-IFNa Ab titres, C3 concentrations and anti-ds DNA Ab titres) data (see supplementary Table S1 and supplementary materials and methods, available at Rheumatology Online). RNA was extracted from these samples, and was also re-extracted from baseline (month 0) and day 168 (month 6) PAXgene tubes stored at À80 from the same patients, and from 10 healthy volunteers (described in [3] ). RNA extraction and hybridization of HGU133 Plus2.0 arrays (Affymetrix, High Wycombe, UK) are described in the supplementary material and methods, available at Rheumatology Online. The Affymetrix.CEL files were deposited in the Gene Expression Omnibus of the National Center for Biotechnology Information, and are accessible through Gene Expression Omnibus accession number GSE72754.
Analysis of the gene expression data was performed on GeneSpring (Agilent, Santa Clara, CA) after normalization by robust multi-array analysis [6] . In order to mine our microarray data, we looked at correlations between serum neutralizing anti-IFNa Ab titres and differences in gene expression compared with baseline. We used several time points from the same patients, in view of the strong changes in anti-IFNa Ab titres over time, to increase the sensitivity of our analyses. Pathway analyses were done using DAVID [7, 8] . Calculation of the IFN [9] and B cell scores are described in the supplementary materials and methods, available at Rheumatology Online. Statistical analyses were performed on Prism v5.0 software. Correlations with serum neutralizing anti-IFNa Ab titres were evaluated using non-parametric tests (Spearman r). Between-group differences in B cell score evolution over time was evaluated using a KruskalWallis test. Additional gene set enrichment analyses were performed using all samples from the initial IFN-K trial (GSE39088), as well as samples from 10 SLE patients with nephritis, before administration of immunosuppressive therapy (GSE72747), IFNa-stimulated control whole blood cells (GSE39088) and CpG-stimulated purified B cells from healthy individuals (GSE45113). [10] A description of these samples is provided in supplementary Table S2 , available at Rheumatology Online.
Results
As described previously, 10 out of 21 patients who received IFN-K (mainly in the 120 and 240 mg groups) developed neutralizing anti-IFNa Abs, which were still detectable in 6 of them at last follow-up visit (range of persistence: 1681558 days, see supplementary Fig. S1 , available at Rheumatology Online). Neutralization studies on 13 different IFNa subtypes were performed using sera from 2 IFN-Ktreated patients, and compared with the neutralization pattern of 9F3, an anti-IFNa2b mAb. The results displayed in supplementary Table S3 , available at Rheumatology Online, confirmed the polyclonal nature of the neutralizing Ab response induced by IFN-K.
Extended follow-up data were collected in 6 out of the 21 IFN-Ktreated patients. One of them (in the 240 mg group) did not have a positive IFN gene signature at baseline. In the five other patients, normalization of the IFN signature was observed in two of them who had developed moderate or high titres neutralizing anti-IFNa antibodies (Fig. 1A) . Accordingly, there was a significant correlation between serum neutralizing anti-IFNa Ab titres and decreased expression of IFN-induced genes (Fig. 1B) . There was also a moderate correlation between increase in serum C3 and neutralizing anti-IFNa Ab titres, but the P-value was not significant (r = 0.32, P = 0.054) (Fig. 1C) . Serum anti dsDNA Ab titres increased in one patient who did not develop neutralizing anti-IFNa Abs, and were stable in all other patients (Fig. 1D ).
In these 6 patients, serum anti-IFNa neutralizing antibody titres displayed a strong (À0.9 < r <À0.7) negative correlation with decreased expression of 156 transcripts (supplementary Table S4 , available at Rheumatology Online). Pathway analyses showed that these transcripts were significantly enriched in immunoglobulin genes (supplementary Table S5 , available at Rheumatology Online). Gene set enrichment analyses showed that the majority of them were overexpressed in SLE patients compared with in controls. These transcripts were also induced by IFNa in control cells, thereby confirming that they are IFNa-dependent. Finally, many of them were (Fig. 2A) .
We designed a score using the 10 (out of 156 listed above) transcripts that were most overexpressed in C27high CpG-stimulated B cells (Fig. 2A , supplementary Table S6 , available at Rheumatology Online). Not surprisingly, decrease in the CpG-stimulated B cell score correlated significantly with serum anti-IFNa neutralizing Ab titres in the extended follow-up group of patients (Fig. 2B) . Because the observed correlation was driven by two patients with high neutralizing Ab titres, we returned to the original phase I/II trial data on all patients in order to increase sample size. We found that IFN-K significantly decreased the expression of these transcripts at day 112 and at day 168 in patients with a positive IFN signature at baseline, compared with IFN signature negative or placebo-treated patients (Fig. 2C) .
Discussion
Extended follow-up data from SLE patients included in the phase I/II IFN-K trial demonstrate that IFN-K induces not only binding, but also neutralizing anti-IFNa Abs, mainly in the higher dose groups. The neutralizing response is polyclonal and extends to numerous IFNa subtypes. Inhibition showing the changes from day 0 in the expression of the 10 probe sets used in the B cell score in all patients included in the phase I/II trial. The differences in the average log2 expression of each of these probe sets between the indicated day and day 0 were calculated for patients treated with placebo (n = 7), IFN signatureÀnegative (n = 7) and IFN signatureÀpositive (n = 12) patients treated with IFN-K. *P < 0.05 using the KruskalÀWallis tests.
of the IFN signature correlates with serum neutralizing anti-IFNa Abs. In addition, in vivo IFNa neutralization is associated with decreased expression of transcripts associated with B cell activation in peripheral blood, an observation that we could extend from the small subset of patients included in the extended follow-up, to the whole population of IFN-Ktreated patients.
More efficient target neutralization by a polyclonal, rather than a monoclonal antibody response is a wellestablished concept, and experimental evidence confirms the synergistic blocking effects of a mix, compared with single mAbs [11] . In the case of IFNa, the ability of such monoclonal Abs to inhibit each individual subtype is variable, and it is possible that some in vivo IFNa activity remains even under therapy. The observation that rontalizumab induces clinical improvement in patients with little or no in vivo IFNa bioactivity, but not in patients with higher levels, is further indirect support in favour of this hypothesis [12] . In contrast, the polyclonal anti-IFNa response induced by IFN-K enhances the probability of neutralization of all IFNa subtypes. In addition, production of higher titres of anti-IFNa Abs in IFN signaturepositive patients results in IFN-blocking activity, even in patients with elevated IFNa bioactivity [3] .
Further data mining indicated that IFN-Kinduced antiIFNa Abs decreased the expression of immunoglobulin and other B cellassociated transcripts. This observation is in line with the known direct and indirect effects of IFNa on B cell activation and differentiation [13] . Whether this effect of IFN-K on circulating B cells will affect activity and size of the autoAb-producing pool of long-lived plasma cells in lupus will be key in evaluating the diseasemodifying effect of IFNa neutralization in SLE.
In conclusion, these observations confirmed the broad IFNa-neutralizing ability of IFN-K, and indicate that further evaluation of the therapeutic effects of the drug in a large placebo-controlled trial is warranted.
